Terms: = Head and neck cancer AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR AND Treatment
115 results:
1. Macrophages: plastic participants in the diagnosis and treatment of head and neck squamous cell carcinoma.
Lin C; Chu Y; Zheng Y; Gu S; Hu Y; He J; Shen Z
Front Immunol; 2024; 15():1337129. PubMed ID: 38650924
[TBL] [Abstract] [Full Text] [Related]
2. New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy.
Chowaniec H; Ślubowska A; Mroczek M; Borowczyk M; Braszka M; Dworacki G; Dobosz P; Wichtowski M
Front Immunol; 2024; 15():1375433. PubMed ID: 38576614
[TBL] [Abstract] [Full Text] [Related]
3. Efficacy of the induced pluripotent stem cell derived and engineered CD276-targeted car-NK cells against human esophageal squamous cell carcinoma.
Lin X; Guan T; Xu Y; Li Y; Lin Y; Chen S; Chen Y; Wei X; Li D; Cui Y; Lin Y; Sun P; Guo J; Li C; Gu J; Yang W; Zeng H; Ma C
Front Immunol; 2024; 15():1337489. PubMed ID: 38566988
[TBL] [Abstract] [Full Text] [Related]
4. Evaluation of a novel model incorporating serological indicators into the conventional TNM staging system for nasopharyngeal carcinoma.
Ding C; Dai DY; Luo ZK; Wang GY; Dong Z; Qin GJ; Du XJ; Ma J
Oral Oncol; 2024 Apr; 151():106725. PubMed ID: 38430711
[TBL] [Abstract] [Full Text] [Related]
5. CD44v6 specific car-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma.
Ciulean IS; Fischer J; Quaiser A; Bach C; Abken H; Tretbar US; Fricke S; Koehl U; Schmiedel D; Grunwald T
Front Immunol; 2023; 14():1290488. PubMed ID: 38022580
[TBL] [Abstract] [Full Text] [Related]
6. The role of podoplanin inhibitors in controlling oral cancer progression.
Sayuddin ENEN; Taher M; Arzmi MH; Burhanudin NA; Rostam MA
Arch Oral Biol; 2024 Jan; 157():105841. PubMed ID: 37952507
[TBL] [Abstract] [Full Text] [Related]
7. Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.
Agosti E; Zeppieri M; De Maria L; Tedeschi C; Fontanella MM; Panciani PP; Ius T
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894718
[TBL] [Abstract] [Full Text] [Related]
8. The PD-1- and LAG-3-targeting bispecific molecule tebotelimab in solid tumors and hematologic cancers: a phase 1 trial.
Luke JJ; Patel MR; Blumenschein GR; Hamilton E; Chmielowski B; Ulahannan SV; Connolly RM; Santa-Maria CA; Wang J; Bahadur SW; Weickhardt A; Asch AS; Mallesara G; Clingan P; Dlugosz-Danecka M; Tomaszewska-Kiecana M; Pylypenko H; Hamad N; Kindler HL; Sumrow BJ; Kaminker P; Chen FZ; Zhang X; Shah K; Smith DH; De Costa A; Li J; Li H; Sun J; Moore PA
Nat Med; 2023 Nov; 29(11):2814-2824. PubMed ID: 37857711
[TBL] [Abstract] [Full Text] [Related]
9. Clinical Pharmacology Profile of AMG 119, the First Chimeric Antigen Receptor T (car-T) Cell Therapy Targeting Delta-Like Ligand 3 (DLL3), in Patients with Relapsed/Refractory Small Cell Lung cancer (SCLC).
Zhou D; Byers LA; Sable B; Smit MD; Sadraei NH; Dutta S; Upreti VV
J Clin Pharmacol; 2024 Mar; 64(3):362-370. PubMed ID: 37694295
[TBL] [Abstract] [Full Text] [Related]
10. Travel-associated cost savings to patients and the health system through provision of specialist head and neck surgery outreach clinics in rural New South Wales, Australia.
Venchiarutti RL; Pearce A; Mathers L; Dawson T; Ch'ng S; Shannon K; Clark JR; Palme CE
Aust J Rural Health; 2023 Oct; 31(5):932-943. PubMed ID: 37501345
[TBL] [Abstract] [Full Text] [Related]
11. Recent advances and future perspectives of car-T cell therapy in head and neck cancer.
Hu C; Liu M; Li Y; Zhao Y; Sharma A; Liu H; Schmidt-Wolf IGH
Front Immunol; 2023; 14():1213716. PubMed ID: 37457699
[TBL] [Abstract] [Full Text] [Related]
12. c-Met is a chimeric antigen receptor T-cell target for treating recurrent nasopharyngeal carcinoma.
Huo Q; Lv J; Zhang J; Huang H; Hu H; Zhao Y; Zhang X; Wang Y; Zhou Y; Qiu J; Ye Y; Huang A; Chen Y; Qin L; Qin D; Li P; Cai G
Cytotherapy; 2023 Oct; 25(10):1037-1047. PubMed ID: 37436338
[TBL] [Abstract] [Full Text] [Related]
13. A novel microenvironment regulated system car-T (MRS.car-T) for immunotherapeutic treatment of esophageal squamous carcinoma.
Wang L; Wang X; Wu Y; Wang J; Zhou W; Wang J; Guo H; Zhang N; Zhang L; Hu X; Zhao Y; Miao J; Zhang Z; Chard Dunmall LS; Zhang D; Lemoine NR; Cheng Z; Wang Y
Cancer Lett; 2023 Aug; 568():216303. PubMed ID: 37422126
[TBL] [Abstract] [Full Text] [Related]
14. Intratumoral pan-ErbB targeted car-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study.
Papa S; Adami A; Metoudi M; Beatson R; George MS; Achkova D; Williams E; Arif S; Reid F; Elstad M; Beckley-Hoelscher N; Douri A; Delord M; Lyne M; Shivapatham D; Fisher C; Hope A; Gooljar S; Mitra A; Gomm L; Morton C; Henley-Smith R; Thavaraj S; Santambrogio A; Andoniadou C; Allen S; Gibson V; Cook GJR; Parente-Pereira AC; Davies DM; Farzaneh F; Schurich A; Guerrero-Urbano T; Jeannon JP; Spicer J; Maher J
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37321663
[TBL] [Abstract] [Full Text] [Related]
15. Identification of crucial genes involved in thyroid cancer development.
Kalarani IB; Sivamani G; Veerabathiran R
J Egypt Natl Canc Inst; 2023 May; 35(1):15. PubMed ID: 37211566
[TBL] [Abstract] [Full Text] [Related]
16. Current progress in chimeric antigen receptor-modified T cells for the treatment of metastatic breast cancer.
Yin L; Chen GL; Xiang Z; Liu YL; Li XY; Bi JW; Wang Q
Biomed Pharmacother; 2023 Jun; 162():114648. PubMed ID: 37023621
[TBL] [Abstract] [Full Text] [Related]
17. Prognostic significance of pre- and post-treatment hematological biomarkers in patients with head and neck cancer treated with chemoradiotherapy.
Iwasa YI; Shimizu M; Matsuura K; Hori K; Hiramatsu K; Sugiyama K; Yokota Y; Kitano T; Kitoh R; Takumi Y
Sci Rep; 2023 Mar; 13(1):3869. PubMed ID: 36890182
[TBL] [Abstract] [Full Text] [Related]
18. A Clinical Series in Patients with Naso-Pharyngeal cancer and Their Outcomes with Stent Graft treatment for Sentinel Bleeding to Prevent Frank carotid Rupture.
Li W; Chen M; Zhang Y; Zhang H; Li C
Ann Vasc Surg; 2023 May; 92():111-117. PubMed ID: 36642167
[TBL] [Abstract] [Full Text] [Related]
19. A drug screening to identify novel combinatorial strategies for boosting cancer immunotherapy efficacy.
Zhang Z; Wang G; Zhong K; Chen Y; Yang N; Lu Q; Yuan B; Wang Z; Li H; Guo L; Zhang R; Wu Z; Zheng M; Zhao S; Tang X; Shao B; Tong A
J Transl Med; 2023 Jan; 21(1):23. PubMed ID: 36635683
[TBL] [Abstract] [Full Text] [Related]
20. Usefulness of Nutrition and Inflammation Assessment Tools in Esophageal cancer treatment.
Aoyama T; Kazama K; Maezawa Y; Hara K
In Vivo; 2023; 37(1):22-35. PubMed ID: 36593006
[TBL] [Abstract] [Full Text] [Related]
[Next]
